# Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy

> **NCT05560308** · NA · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 50 (estimated)

## Conditions studied

- HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy

## Interventions

- **DRUG:** Trastuzumab Emtansine for Injection
- **DRUG:** Pyrotinib Maleate Tablets

## Key facts

- **NCT ID:** NCT05560308
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-30
- **Primary completion:** 2024-08-31
- **Final completion:** 2025-08-23
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05560308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05560308, "Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05560308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*